Molecular Oncology (Aug 2020)
Towards a cancer mission in Horizon Europe: recommendations
- Anton Berns,
- Ulrik Ringborg,
- Julio E. Celis,
- Manuel Heitor,
- Neil K. Aaronson,
- Nancy Abou‐Zeid,
- Hans‐Olov Adami,
- Kathi Apostolidis,
- Michael Baumann,
- Alberto Bardelli,
- René Bernards,
- Yvonne Brandberg,
- Carlos Caldas,
- Fabien Calvo,
- Caroline Dive,
- Angelika Eggert,
- Alexander Eggermont,
- Carolina Espina,
- Frederik Falkenburg,
- Jérôme Foucaud,
- Douglas Hanahan,
- Ulrike Helbig,
- Bengt Jönsson,
- Mette Kalager,
- Sakari Karjalainen,
- Miklós Kásler,
- Pamela Kearns,
- Klas Kärre,
- Denis Lacombe,
- Francesco deLorenzo,
- Françoise Meunier,
- Gerd Nettekoven,
- Simon Oberst,
- Péter Nagy,
- Thierry Philip,
- Richard Price,
- Joachim Schüz,
- Eric Solary,
- Peter Strang,
- Josep Tabernero,
- Emile Voest
Affiliations
- Anton Berns
- The Netherlands Cancer Institute Amsterdam the Netherlands
- Ulrik Ringborg
- European Academy of Cancer Sciences Stockholm Sweden
- Julio E. Celis
- European Academy of Cancer Sciences Stockholm Sweden
- Manuel Heitor
- Ministry for Science, Technology and Higher Education Lisbon Portugal
- Neil K. Aaronson
- The Netherlands Cancer Institute Amsterdam the Netherlands
- Nancy Abou‐Zeid
- Fondation ARC pour la recherché sur le cancer Villejuif France
- Hans‐Olov Adami
- Karolinska Institutet Stockholm Sweden
- Kathi Apostolidis
- European Cancer Patient Coalition Brussels Belgium
- Michael Baumann
- European Academy of Cancer Sciences Stockholm Sweden
- Alberto Bardelli
- The European Association for Cancer Research Nottingham UK
- René Bernards
- The Netherlands Cancer Institute Amsterdam the Netherlands
- Yvonne Brandberg
- Karolinska Institutet Stockholm Sweden
- Carlos Caldas
- European Academy of Cancer Sciences Stockholm Sweden
- Fabien Calvo
- Gustave Roussy Cancer Campus Grand Paris Villejuif France
- Caroline Dive
- The European Association for Cancer Research Nottingham UK
- Angelika Eggert
- Charite‐Universitatsmedizin Berlin Germany
- Alexander Eggermont
- European Academy of Cancer Sciences Stockholm Sweden
- Carolina Espina
- International Agency for Research on Cancer (IARC/WHO) Lyon France
- Frederik Falkenburg
- Dutch Cancer Society Amsterdam the Netherlands
- Jérôme Foucaud
- French National Cancer Institute (INCa) Boulogne Billancourt France
- Douglas Hanahan
- Swiss Institute for Experimental Cancer Research (ISREC) Federal Institute of Technology in Lausanne (EPFL) Lausanne Switzerland
- Ulrike Helbig
- German Cancer Aid Bonn Germany
- Bengt Jönsson
- Stockholm School of Economics Stockholm Sweden
- Mette Kalager
- Institute of Health and Society University of Oslo Oslo Norway
- Sakari Karjalainen
- Association of European Cancer Leagues (ECL) Brussels Belgium
- Miklós Kásler
- Ministry of Human Resources Budapest Hungary
- Pamela Kearns
- SIOPE Head Office Brussels Belgium
- Klas Kärre
- The Swedish Cancer Society Stockholm Sweden
- Denis Lacombe
- EORTC Headquarters Brussels Belgium
- Francesco deLorenzo
- European Cancer Patient Coalition Brussels Belgium
- Françoise Meunier
- Federation of European Academies of Medicine Brussels Belgium
- Gerd Nettekoven
- German Cancer Aid Bonn Germany
- Simon Oberst
- Cancer Research UK Cambridge Centre Cambridge UK
- Péter Nagy
- Organisation of European Cancer Institutes (OECI) Brussels Belgium
- Thierry Philip
- Organisation of European Cancer Institutes (OECI) Brussels Belgium
- Richard Price
- The European Cancer Organisation (ECCO) Brussels Belgium
- Joachim Schüz
- International Agency for Research on Cancer (IARC/WHO) Lyon France
- Eric Solary
- Fondation ARC pour la recherché sur le cancer Villejuif France
- Peter Strang
- Karolinska Institutet Stockholm Sweden
- Josep Tabernero
- Vall d’Hebron University Hospital and Institute of Oncology (VHIO) Barcelona Spain
- Emile Voest
- The Netherlands Cancer Institute Amsterdam the Netherlands
- DOI
- https://doi.org/10.1002/1878-0261.12763
- Journal volume & issue
-
Vol. 14,
no. 8
pp. 1589 – 1615
Abstract
A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research–care–prevention continuum has the potential to achieve in 2030 a 10‐year cancer‐specific survival for 75% of patients diagnosed in European Union (EU) member states with a well‐developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high‐quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science‐driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC‐like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long‐term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans‐border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence‐based advice.
Keywords
- cancer mission
- cancer research/care/prevention continuum
- comprehensive cancer centres
- European healthcare systems
- patient empowerment
- science policy